Study #2016-0861
A Phase II, Single-Arm Open-Label Study Of The Combination Of Atezolizumab And Bevacizumab In Rare Solid Tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
Atezolizumab, Bevacizumab
Description
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Merkel Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Stage III Merkel Cell Carcinoma AJCC V7, Stage III Nasopharyngeal Carcinoma AJCC V7, Stage III Pleural Malignant Mesothelioma AJCC V7, Stage IV Merkel Cell Carcinoma AJCC V7, Stage IV Nasopharyngeal Carcinoma AJCC V7, Stage IV Pleural Malignant Mesothelioma AJCC V7, Stage IVA Nasopharyngeal Carcinoma AJCC V7, Stage IVB Nasopharyngeal Carcinoma AJCC V7, Stage IVC Nasopharyngeal Carcinoma AJCC V7, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Study phase:
Phase II
Physician name:
Kanwal Raghav
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.